BioMarin develops gene therapy treatment for PKU
Client(s) BioMarin Pharmaceutical Inc.
Jones Day is representing BioMarin Pharmaceutical Inc. in its development of a phenylalanine hydroxylase ("PAH") gene therapy treatment for phenylketonuria ("PKU").